Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Journal of Alzheimer's Disease Année : 2021

Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study

Résumé

This longitudinal study evaluates the prognostic impact of amyloid PET in patients suspected of Alzheimer’s disease and presenting with isolated cerebrospinal fluid (CSF) increases in P-Tau proteins (NCT02556502). The rate of conversion, based on the DSM-5 criteria and all collected data (average follow-up of 39.2±13.2 months), was determined by a panel of experts blinded to the PET results and was 75%(6/8) for positive and 35%(6/17) for negative baseline amyloid PET. In this population with isolated CSF increases in P-Tau, a positive baseline amyloid PET was associated with greater than twice the proportion of dementia conversions within the following three years.
Fichier non déposé

Dates et versions

hal-03266987 , version 1 (22-06-2021)

Identifiants

Citer

Amory Jardel, Lucie Hopes, Catherine Malaplate, Véronique Roch, Chloé Manca, et al.. Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study. Journal of Alzheimer's Disease, 2021, 80 (4), pp.1389-1394. ⟨10.3233/JAD-201435⟩. ⟨hal-03266987⟩
80 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More